Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Pirtobrutinib in Hepatic Impairment
NCT06190691Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration, Time to Maximum Observed Plasma Concentration and 6 more. Started Dec 2020; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06190691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190691.